In the News

MSK leads the way in optimizing radiation treatment for breast cancer patients.

At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.

Scientists have learned that cutting a T cell’s brakes can have unexpected consequences.

Fifteen young scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 13, 2026, as part of Memorial Sloan Kettering’s 47th annual academic convocation.

A collaboration between MSK and Weill Cornell Medicine discovered a new relationship between cancer cells and the immune system, and shows how cancer can selfishly hijack a normally helpful immune pathway.

Learn how radiation oncologists at Memorial Sloan Kettering are making radiation therapy for metastatic cancer more effective, with fewer side effects, including a new advance called ECHO.

The third annual research symposium introduces high school students and teachers to several topics in cancer research.

New MSK research uncovers clues about how cells control a key DNA repair protein; develops a new method for studying gene amplifications in cancer; sheds new light on tumor suppressor genes; shows MSK-IMPACT® could be used for HLA genotype screening to predict response to cellular therapies; identifies a possible strategy to overcome immune evasion in ovarian cancer; and finds strong support for telemedicine visits among cancer patients.

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.